[

remdesivir

]
PAGE 4

Zydus Cadila inks licensing pact with Gilead for remdesivir

Remdesivir, the investigational drug from Gilead Sciences Inc, has been issued an ‘emergency use authorisation’ (EUA) by the United States Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of coronavirus, Zydus Cadila said in a statement.
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany(REUTERS)
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany(REUTERS)
Updated on Jun 12, 2020 09:28 PM IST
Copy Link
New Delhi | By Press Trust of India

Coronavirus pandemic: Remdesivir slows Covid-19 progression in macaques

Early treatment with the antiviral drug remdesivir has been found to reduce viral load and prevent lung disease in macaques infected with SARS-CoV-2 that causes COVID-19, according to a study.
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/Files(REUTERS)
Two ampules of Remdesivir are pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS/Files(REUTERS)
Updated on Jun 10, 2020 03:23 PM IST
Copy Link
Washington DC | By Press Trust of India | Posted by: Alfea Jamal

Gilead’s remdesivir slows progression of Covid-19 in monkeys: Study

In the study, macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs, according to the study authors.
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir are capped at a Gilead Sciences facility in La Verne, California, U.S.(Reuters)
Updated on Jun 09, 2020 03:43 PM IST
Copy Link
Reuters | By Reuters| Posted by Susmita Pakrasi

Plant-derived drug under testing, cancer drug shows promise: Covid-19 vaccine update

Japan’s Fujifilm Holdings Corp said its research on Avigan as a potential treatment for Covid-19 may drag on until July.
Image for representation: Small bottles labelled with a ‘Vaccine COVID-19’ sticker and a medical syringe are seen in this illustration.(REUTERS)
Image for representation: Small bottles labelled with a ‘Vaccine COVID-19’ sticker and a medical syringe are seen in this illustration.(REUTERS)
Updated on Jun 07, 2020 04:18 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com | Edited by Sparshita Saxena

News updates from Hindustan Times: Maharashtra banks on Remdesivir drug to fight Covid-19, will buy 10K vials and all the latest news

Here are today’s top news, analysis and opinion. Know all about the latest news and other news updates from Hindustan Times.
Maharashtra CM Uddhav Thackeray at Matoshree in Mumbai. Maharashtra government on Saturday said it will be procuring 10,000 vials of the drug to combat the pandemic in the state.(Kunal Patil/HT Photo)
Maharashtra CM Uddhav Thackeray at Matoshree in Mumbai. Maharashtra government on Saturday said it will be procuring 10,000 vials of the drug to combat the pandemic in the state.(Kunal Patil/HT Photo)
Published on Jun 06, 2020 08:55 PM IST
Copy Link
Hindustan Times, New Delhi | By hindustantimes.com

News updates from Hindustan Times: Terrorist trying to infiltrate into India killed in south Kashmir’s Tral and all the latest news

Here are today’s top news, analysis and opinion. Know all about the latest news and other news updates from Hindustan Times.
An Indian Army jawan patrolling at the Line of Control (LoC) in Poonch district of Jammu and Kashmir.(PTI file photo)
An Indian Army jawan patrolling at the Line of Control (LoC) in Poonch district of Jammu and Kashmir.(PTI file photo)
Updated on Jun 02, 2020 08:46 AM IST
Copy Link
Hindustan Times, New Delhi | By HT Correspondent

India’s drug regulator grants Gilead Sciences marketing authorisation for remdesivir

The approval process for remdesivir was accelerated in view of the emergency situation and the unmet need for medicines in light of the coronavirus outbreak.
The approval was given following consultation with the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO).(Reuters)
The approval was given following consultation with the subject expert committee of the Central Drugs Standard Control Organisation (CDSCO).(Reuters)
Updated on Jun 02, 2020 07:33 AM IST
Copy Link
New Delhi, Delhi | By Press Trust of India | Posted by: Shivani Kumar

Taiwan approves Gilead’s remdesivir to treat Covid-19

California-based Gilead has said it will donate 1.5 million doses of remdesivir, enough to treat at least 140,000 patients, to combat the global pandemic.
Governments are racing to bolster supplies of remdesivir, which US regulators this month approved for emergency use.(via REUTERS)
Governments are racing to bolster supplies of remdesivir, which US regulators this month approved for emergency use.(via REUTERS)
Published on May 30, 2020 12:13 PM IST
Copy Link
Taipei | By Reuters | Posted by: Prashasti Singh

Covid-19: US pharma giant seeks marketing authorisation from India for remdesivir

This comes in the backdrop of two Indian pharmaceutical companies -- Cipla and Hetero Labs -- applying to the drug regulator seeking permission to manufacture and sell remdesivir in India. 
Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said.(Reuters)
Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said.(Reuters)
Updated on May 30, 2020 05:42 AM IST
Copy Link
New Delhi | By Press Trust of India | Posted by: Prashasti Singh

Remdesivir most beneficial for severely ill Covid-19 patients, say researchers

The median recovery time for patients administered remdesivir was 11 days, compared 10 15 for those on placebo. Recovery was defined as the patient being discharged from hospital or found to be medically stable enough to be discharged.
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany as the spread of coronavirus disease continues.(Reuters File Photo)
An ampule of Ebola drug Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany as the spread of coronavirus disease continues.(Reuters File Photo)
Updated on May 23, 2020 09:24 PM IST
Copy Link
Hindustan Times, Washington | By Yashwant Raj | Posted by Kanishka Sarkar

US pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India

Officials of the Union Health Ministry, along with the DCGI held a discussion with the representatives of Gilead Sciences on Wednesday to prepare a road map for introducing remdesivir in India.
Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of Remdesivir.(Reuters)
Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of Remdesivir.(Reuters)
Updated on May 21, 2020 07:32 PM IST
Copy Link
New Delhi, Delhi, India | By Press Trust of India | Posted by: Shivani Kumar

Jubilant Life Sciences Limited ties up with Gilead for remdesivir

Remdesivir, an investigational anti-viral therapy developed by Gilead, received Emergency Use Authorisation (EUA) by USFDA to treat Covid-19.
An ampule of remdesivir is pictured at the University Hospital Eppendorf (UKE) in Hamburg, Germany, on April 8.(Reuters Photo)
An ampule of remdesivir is pictured at the University Hospital Eppendorf (UKE) in Hamburg, Germany, on April 8.(Reuters Photo)
Updated on May 12, 2020 09:31 PM IST
Copy Link
Hindustan Times, New Delhi | By HT Correspondent

Isolation pods, deployable hospitals, antibody gel: India’s tools to tackle pandemic

The Compendium was launched by Council of Scientific and Industrial Research which has information on 200 Covid-19 technologies, ongoing research and technologies already available for commercialisation.
Indian health workers organize the samples at a COVID-19 testing center in New Delhi.(AP)
Indian health workers organize the samples at a COVID-19 testing center in New Delhi.(AP)
Updated on May 07, 2020 11:01 AM IST
Copy Link
By Jayashree Nandi

What is WHO Covid-19 ‘Solidarity Trial’? How will it be conducted in India

Hospitals from four cities in Gujarat - Ahmedabad, Vadodara, Surat and Rajkot - will participate in the WHO’s international clinical trial, a senior state health official said.
A laboratory worker removes a test tube containing a patient's sample from a box during coronavirus detection tests in the virology research labs.(Bloomberg)
A laboratory worker removes a test tube containing a patient's sample from a box during coronavirus detection tests in the virology research labs.(Bloomberg)
Updated on May 05, 2020 02:43 PM IST
Copy Link
Hindustan Times, New Delhi | By Hindustantimes.com | Edited by Sparshita Saxena

India a step closer to making key drug to treat Covid-19

India is part of the World Health Organisation’s Solidarity Trials for the cure of Covid-19 and has received 1000 doses of the drug for testing.
Remdesivir, manufactured by Gilead Sciences, is the first drug to treat Covid-19 approved for emergency use in the US based on clinical data .(AFP File Photo)
Remdesivir, manufactured by Gilead Sciences, is the first drug to treat Covid-19 approved for emergency use in the US based on clinical data .(AFP File Photo)
Updated on May 05, 2020 04:15 AM IST
Copy Link
Hindustan Times, New Delhi | By Jayashree Nandi

What is Remdesivir? How can it help in Covid-19 treatment

The US has allowed the emergency use of experimental antiviral drug Remdesivir for coronavirus treatment.
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, US.(REUTERS)
A lab technician visually inspects a filled vial of investigational coronavirus disease (COVID-19) treatment drug remdesivir at a Gilead Sciences facility in La Verne, California, US.(REUTERS)
Updated on May 03, 2020 09:56 AM IST
Copy Link
Hindustan Times, New Delhi | By HT Correspondent | Edited by Sparshita Saxena

US okays remdesivir for emergency Covid-19 use

The emergency authorisation allows products to be used for treatment without full data on their safety and efficacy, which has to be still submitted as trials continue.
Angry protesters hold banners during a demonstration demanding the reopening of the US economy, in Chicago, Illinois.
Angry protesters hold banners during a demonstration demanding the reopening of the US economy, in Chicago, Illinois.
Published on May 03, 2020 03:27 AM IST
Copy Link
Hindustan Times, New Delhi/Washington | By Sanchita Sharma and Yashwant Raj, New Delhi/ Washington

Remdesivir gets US emergency approval for treating Covid-19 patients: Know all about the antiviral drug

Remdesivir, when administered by an intravenous infusion, helped patients recover on an average in 11 days, compared to 15 days taken by those on placebo.
File photo of vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir being capped at a Gilead Sciences facility in La Verne, California, March, 2020.(via REUTERS)
File photo of vials of investigational coronavirus disease (COVID-19) treatment drug remdesivir being capped at a Gilead Sciences facility in La Verne, California, March, 2020.(via REUTERS)
Updated on May 02, 2020 10:23 AM IST
Copy Link
Hindustan Times, New Delhi | By Sanchita Sharma

US issues emergency approval for remdesivir for Covid-19 patients

President Donald Trump announced the news at the White House alongside Gilead CEO Daniel O’Day and Food and Drug Administration Commissioner Stephen Hahn.
The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.(REUTERS)
The FDA acted after preliminary results from a government-sponsored study showed that the drug, remdesivir, shortened the time to recovery by 31%, or about four days on average, for hospitalized COVID-19 patients.(REUTERS)
Updated on May 02, 2020 04:49 AM IST
Copy Link
Washington | By Associated Press

India must consider ways to get access to remdesivir: Nirmal K Ganguly

Remdesivir is an experimental antiviral drug developed by the US-based pharma major Gilead Sciences. It failed in trials against the Ebola virus and was found to have limited effects among patients in Wuhan, China, where the illness was first detected last year.
(special arrangement)
(special arrangement)
Updated on May 01, 2020 11:41 PM IST
Copy Link
Hindustan Times, New Delhi | By Sanchita Sharma

Indian-American Aruna Subramanian leading trial of remdesivir in Covid-19 treatment

Remdesivir is not yet licensed or approved anywhere globally and has not been demonstrated to be safe or effective for the treatment of the Covid-19.
Drug remdesivir has reached phase three of clinical trial considered to be the final step in the process of the drug approval.(Reuters Photo)
Drug remdesivir has reached phase three of clinical trial considered to be the final step in the process of the drug approval.(Reuters Photo)
Updated on May 01, 2020 11:42 AM IST
Copy Link
Hindustan Times, New Delhi | By HT Correspondent

Remdesivir shows ‘clear-cut’ effect in treating coronavirus: Anthony Fauci

Fauci, speaking at the White House, said “the data shows remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery.”
Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci said a smaller Chinese study released separately on Wednesday showing no benefits from remdesivir was “not an adequate study.”(AFP)
Director of the National Institute of Allergy and Infectious Diseases Anthony Fauci said a smaller Chinese study released separately on Wednesday showing no benefits from remdesivir was “not an adequate study.”(AFP)
Published on Apr 29, 2020 11:52 PM IST
Copy Link
Washington | By Agence France-Presse

Gilead’s potential coronavirus treatment gets FDA’s orphan drug label

The announcement comes days after U.S. President Donald Trump called on the FDA to streamline its approval process for treatments such as remdesivir, which is currently being tested in clinical trials, with results expected as early as next month.
There are currently no approved treatments or preventive vaccines for COVID-19, the disease caused by the coronavirus.(AP)
There are currently no approved treatments or preventive vaccines for COVID-19, the disease caused by the coronavirus.(AP)
Updated on Mar 24, 2020 06:20 PM IST
Copy Link
Bengaluru | By Reuters
SHARE
  • 4
Story Saved
×
Saved Articles
My Reads
Sign out
New Delhi 0C
Sunday, October 24, 2021